Acelyrin Raises $540M IPO; Shares Shut Up 30% on First Day of Buying and selling

Woodland Hills-based Acelyrn Inc., which is creating immunology medicine, raised a minimum of $540 million in an preliminary public providing on the Nasdaq market on Might 5  

Buying and selling underneath the image SLRN, Acelyrin supplied 30 million shares at $18 per share. On the shut of buying and selling on Might 5, the share worth had zoomed up 30% to shut at $23.50. 

Acelyrin was based in late 2020 as a medical biopharmaceutical firm targeted on the event of immunological therapies. However in contrast to many different immunology firms whose founders develop particular drug platforms within the lab after which search to commercialize them, Acelyrin has been targeted totally on buying promising drug platforms and taking them via the ultimate phases of growth and medical trials. 

Within the phrases of Acelyrin founder and chief govt Shao-Lee Lin, Acelyrin’s mission is “to determine, purchase, and speed up the event and supply of therapies with the potential to offer clinically significant, differentiated advantages to sufferers primarily based on the science of the targets or traits of the molecules.”   

The corporate shortly amassed an enormous conflict chest, elevating $558 million in simply 21 months, together with $300 million in a sequence C funding spherical that closed in September. 

For instance of its technique, in January, Acelyrin acquired Bethesda, Maryland-based immunotherapy firm ValenzaBio Inc.; monetary phrases of that deal weren’t disclosed. ValenzaBio has a drug in an early-phase examine to deal with thyroid eye illness and one other drug in pre-clinical trial section to deal with chronic urticaria, a pores and skin allergy situation that may function an indicator for different inner illnesses. 

On the time, Lin mentioned of the acquisition, “We’ll proceed to search for extra ‘diamond within the tough’ alternatives as we pursue the acquisition, growth and supply of transformative medicines for sufferers.”  

A lot of the $540 million raised within the IPO will go towards this acquisition and drug growth technique.